$1.97
-0.51%Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, CardioSert, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable robot for various endovascular interventional procedures; and a multi generation pipeline portfolio. It has 42 issued/allowed patents and 23 patent applications pending worldwide. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
MBOT โข NASDAQ
| Microbot Medical Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||||
-13.1M | -11.4M | -10.7M | -13.2M | -11.3M | -9.2M | -7.2M | -7.3M | -7.6M | -9.7M | -921K | -32.7M | -26.4M | -28.5M | -21.3M | -25.2M | -27M | -29.1M | -25M | -18.9M | |
47K | 91K | 106K | 102K | 76K | 68K | 84K | 54K | 21K | 10K | 17K | 1.3M | 1.1M | 991.7K | 1.2M | 1.5M | 1.7M | 1.2M | 1.2M | 1M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 21.9M | -169.9K | -406.9K | 0.0 | 0.0 | 0.0 | |
1.1M | 1.3M | 1.4M | 1.8M | 1.4M | 1.9M | 1.1M | 1.4M | 479K | 676K | 0.0 | 2M | 2.6M | 2.9M | 3.3M | 3.9M | 4.2M | 0.0 | 0.0 | 0.0 | |
0.0 | 234K | 718K | -7K | 0.0 | -70K | -121K | 74K | 2.3M | 7.3M | 7K | 374.3K | -550.2K | 6M | -27.9M | -2.9M | -1.9M | 7M | 1.9M | 2.4M | |
-1M | 942K | -11K | -228K | 497K | -18K | -266K | 423K | -83K | 862K | 132K | 1.7M | 0.0 | -1.2M | 810.1K | -1.6M | -1.2M | -1.8M | 1.1M | -630.6K | |
-13M | -8.8M | -8.5M | -11.5M | -9.4M | -7.3M | -6.5M | -5.3M | -4.9M | -786K | -765K | -27.4M | -23.3M | -19.9M | -22.1M | -24.5M | -24.7M | -22.7M | -20.9M | -16.1M | |
INVESTING ACTIVITIES | ||||||||||||||||||||
-60K | -25K | -33K | -84K | -69K | -91K | -216K | -223K | -58K | -25K | -2K | -903.9K | -42.9K | -73.1K | -296.9K | -924K | -716.2K | -337.4K | -1.3M | -1.3M | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (38.5K) | (0.0) | -83.8M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-82.9M | -5.1M | -10.1M | -3.7M | (0.0) | -5M | -2.5M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -687.8K | -16.4M | -10.2M | (0.0) | -5M | -4.8M | -27.9M | (0.0) | |
10.6M | 6.7M | 12.1M | 0.0 | 3.3M | 2.5M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 14.4M | 5.8M | 7.1M | 0.0 | 9.5M | 28.7M | 3.1M | 0.0 | |
0.0 | 0.0 | 3K | -3K | 0.0 | -200K | 259K | 0.0 | 0.0 | 0.0 | 0.0 | 478.3K | -4.7M | 0.0 | 83.8M | 0.0 | -79.8K | 702K | -1M | -38.4K | |
-72.4M | (1.5M) | (2M) | -3.8M | (3.2M) | -2.8M | -2.5M | -223K | -58K | -25K | -2K | -425.6K | (9M) | -10.7M | -3.4M | -924K | (3.7M) | (24.2M) | -27.2M | -1.3M | |
FINANCING ACTIVITIES | ||||||||||||||||||||
86.2M | 7.9M | 6.6M | 4.3M | 0.0 | -3.4M | 36.8M | 0.0 | 12.7M | 0.0 | 25.9M | 18.5M | 23.1M | 19.7M | 19.4M | 6.8M | 29.2M | 18.8M | 6.1M | 35M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 750K | 413K | 1.8M | 12.7M | -211.4K | -176.3K | -161.3K | -20.6K | -153.8K | -163K | -308.8K | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -392.6K | -499.3K | -342.4K | -59.1K | -403.6K | -483.4K | -380.5K | (0.0) | (0.0) | (0.0) | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -18K | 317K | 2.3M | -25.9M | 2M | 533.5K | 6.3M | -65.5K | -48.2K | 584.5K | 127.5K | 0.0 | 0.0 | |
86.2M | 7.9M | 6.6M | 4.3M | 0.0 | -3.4M | 36.8M | -18K | 13M | 3.1M | 413K | 22.2M | 36.4M | 25.7M | 19.1M | 6.6M | 29.8M | 18.8M | 6M | 34.7M | |
CASH FLOW SUMMARY | ||||||||||||||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -2K | -15.9K | -45.7K | -52.7K | -260.6K | 0.0 | 0.0 | 0.0 | |
810K | 646K | -2K | -11.1M | -6.2M | -13.4M | 27.9M | -5.6M | 8.1M | 2.3M | -354K | -5.6M | 22.1M | -4.8M | -6.4M | -18.9M | 8.6M | 20.3M | -42M | 17.3M | |
3.2M | 2.5M | 2.5M | 13.6M | 19.7M | 33.1M | 5.3M | 10.8M | 2.7M | 437K | 25M | 30.6M | 8.5M | 13.3M | 19.7M | 38.6M | 30M | 9.8M | 51.8M | 34.5M | |
4M | 3.2M | 2.5M | 2.5M | 13.6M | 19.7M | 33.1M | 5.3M | 10.8M | 2.7M | 12.1M | 25M | 30.6M | 8.5M | 13.3M | 19.7M | 38.6M | 30M | 9.8M | 51.8M | |
-13.1M | -8.9M | -8.6M | -11.6M | -9.4M | -7.3M | -6.7M | -5.5M | -4.9M | -811K | -767K | -28.3M | -28M | -19.9M | -22.4M | -25.4M | -25.4M | -23.1M | -22.2M | -17.4M |
MBOT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 02, 2026 | June 02, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 26, 2026 | May 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 15, 2026 | May 15, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 14, 2026 | May 14, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 13, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 05, 2026 | May 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 30, 2026 | April 30, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 22, 2026 | April 22, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 14, 2026 | April 14, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 13, 2026 | April 13, 2026 | 2026 |
Continue your MBOT research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.